P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Sylvanie Surget,Sylvanie Surget,Sylvanie Surget,Géraldine Descamps,Géraldine Descamps,Géraldine Descamps,Carole Brosseau,Carole Brosseau,Carole Brosseau,Vincent Normant,Vincent Normant,Vincent Normant,Sophie Maïga,Sophie Maïga,Sophie Maïga,Patricia Gomez-Bougie,Nadège Gouy-Colin,Catherine Godon,Marie C. Béné,Philippe Moreau,Steven Le Gouill,Martine Amiot,Catherine Pellat-Deceunynck +22 more
TL;DR: These data show that RITA, in contrast to nutlin3a, effectively induced apoptosis in a subset of MM cells independently of p53, and could be of interest for patients with a 17p deletion, who are resistant to current therapies.
Journal ArticleDOI
Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.
Florent Malard,Céline Bossard,Eolia Brissot,Patrice Chevallier,Thierry Guillaume,Jacques Delaunay,Jean-François Mosnier,Philippe Moreau,Marc Grégoire,Beatrice Gaugler,Mohamad Mohty +10 more
TL;DR: Evidence is provided for a role of Th17‐mediated responses and a potential new pathophysiological link between PDCs and Th17 in human cutaneous aGVHD and a strong expression of the type I IFN‐inducible protein Mx1 in the skin of the patients with aGV HD.
Journal ArticleDOI
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
Philippe Moreau,Thierry Facon,Cyrille Touzeau,Lotfi Benboubker,Martine Delain,Julie Badamo-Dotzis,Charles Phelps,Christopher Doty,Hans Smit,Nele Fourneau,Ann Forslund,Peter Hellemans,Xavier Leleu +12 more
TL;DR: The maximum tolerated dose (MTD) of quisinostat + bortezomib + dexamethasone in patients with relapsed multiple myeloma was evaluated in a phase-1b, open-label, multicenter, ‘3 + 3’ dose-escalation study.
Journal ArticleDOI
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Parameswaran Hari,M.V. Mateos,Rafat Abonour,Stefan Knop,William I. Bensinger,H. Ludwig,K. Song,Roman Hájek,Philippe Moreau,David S. Siegel,Shibao Feng,Mihaela Obreja,Sanjay K. Aggarwal,K G Iskander,H. Goldschmidt +14 more
TL;DR: It is suggested that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status, and further evaluation is warranted.
Journal ArticleDOI
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Christian Buske,Martin Dreyling,Alberto Alvarez-Larrán,Jane F. Apperley,Luca Arcaini,Corinne Besson,Lars Bullinger,Paolo Corradini,M. Giovanni Della Porta,M.A. Dimopoulos,Shirley D'Sa,Hans Th. Eich,Robin Foà,Paolo Ghia,Maria Gomes da Silva,John G. Gribben,Roman Hájek,Claire N. Harrison,Michael Heuser,Barbara Kiesewetter,J J Kiladjian,Nicolaus Kröger,Philippe Moreau,Jakob Passweg,Flora Peyvandi,Delphine Rea,Josep-Maria Ribera,Tadeusz Robak,J. San Miguel,Valeria Santini,Guillermo Sanz,Pieter Sonneveld,Marie von Lilienfeld-Toal,C M Wendtner,George Pentheroudakis,Francesco Passamonti +35 more
TL;DR: In this paper , the authors discuss clinical evidence and provide expert advice on statements related to the management of patients with hematological malignancies in the COVID-19 pandemic.